|
KMID : 1140120090140030212
|
|
Cancer Prevention Research
2009 Volume.14 No. 3 p.212 ~ p.217
|
|
|
The Clinical Significance of O6-methylguanine-DNAmethyltransferase (MGMT) Depletion in Brain Tumor
|
|
Ju Ji-Hyun
Kang Myoung-Hee
Kim Seok-Hyun
Kim Hoon-Gu
Kang Jung-Hun
Lee Gyeong-Won
Park Kyung-Bum
Lee Won-Sup
Kang Ki-Mun
Chai Gyu-Young
Jung Jin-Myung
Ko Gyung-Hyuck
|
|
|
Abstract
|
|
|
|
O6-methylguanine-DNA-methyltransferase (MGMT) depletion in cancer is prone to DNA damage from alkylating agents. Evidences suggested that the depletion of DNA repair protein MGMT by the promoter methylation might be associated with improved survival in glioblastomas treated with radiotherapy alone or in combination with alkylating agents. In this study, we therefore investigated the clinical significances of immunohistochemical MGMT expression in brain tumor treated with RT (radiotherapy) in combination with alkylating agents. Immunohistochemistry was performed with anti-MGMT antibody on 20 paraffinembedded samples from the patients treated with RT in combination with alkylating agents. We found that MGMT-negative group has higher complete remission rates than MGMT-positive group. The results of Kaplan-Meier analysis showed a trend of survival differences between the two groups, but there was no statistical difference. This study suggested MGMT expression in cancer cells serves as an important variable to predict the complete remission in the patients with brain tumor treated with concurrent chemoradiation with alkylating agents.
|
|
|
KEYWORD
|
|
|
MGMT protein, Brain tumor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|